| 3.4 0.025 (0.74%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.2 | 1-year : | 4.91 |
| Resists | First : | 3.59 | Second : | 4.2 |
| Pivot price | 3.27 |
|||
| Supports | First : | 3.18 | Second : | 2.93 |
| MAs | MA(5) : | 3.42 |
MA(20) : | 3.2 |
| MA(100) : | 3.08 |
MA(250) : | 2.99 |
|
| MACD | MACD : | 0.1  |
Signal : | 0 |
| %K %D | K(14,3) : | 70.8 |
D(3) : | 73.4 |
| RSI | RSI(14): 57.9 |
|||
| 52-week | High : | 4.19 | Low : | 2.06 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANIX ] has closed below upper band by 36.2%. Bollinger Bands are 61.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.44 - 3.46 | 3.46 - 3.47 |
| Low: | 3.26 - 3.28 | 3.28 - 3.3 |
| Close: | 3.37 - 3.4 | 3.4 - 3.43 |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Mon, 22 Sep 2025
First-Ever Alpha-lactalbumin Breast Cancer Vaccine: Anixa to Reveal Phase 1 Trial Results at Major Conference - Stock Titan
Tue, 02 Sep 2025
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - PR Newswire
Mon, 01 Sep 2025
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation - Yahoo Finance
Tue, 12 Aug 2025
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 16.5 (%) |
| Shares Short | 411 (K) |
| Shares Short P.Month | 416 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37 % |
| Return on Equity (ttm) | -62.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -10 |
| PEG Ratio | 0 |
| Price to Book value | 6.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|